Применение антагониста лейкотриеновых рецепторов монтелукаста для лечения бронхиальной астмы у детей первых лет жизни

бронхиальная астма, аллергический ринит, монтелукаст, лечение, дети

1. Российская национальная программа "Бронхиальная астма у детей. Стратегия лечения и профилактика". М.: Изд. дом "Атмосфера"; 2008.

2. Ducharme F.M., Di Salvio F. Antileukotriene agents compared to inhaled corticosteroids in the management of recurrent and / or chronic asthma in adults and children. Cochrane Database Syst. Rev. 2004; 1: CD002314.

3. Wright AL, Taussig LM. Lessons from long-term cohort studies. Childhood asthma. Eur Respir J Suppl. 1998; 27: 17S-22S

4. Busse W.W. The role of leukotrienes in asthma and allergic rhinitis. Clin. Exp. Allergy 1996; 26: 868-879.

5. Knorr B., Matz J., Bernstein J.A. et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. J. A. M. A. 1998; 279 (15): 1181-1186.

6. Knorr B., Noonan G., McBurney J. et al. Evaluation of the long-term effect of montelukast in adult (15 years) and pediatric (6- to 14-years) patients. Eur. Respir. J. 1999; 14 (suppl.): 290S.

7. Edelman J.M., Preston S.R., Turpin J.A. et al. Parent and child preference for montelukast, a leukotriene receptor antagonist, compared to inhaled cromolyn in asthmatic children ages 6 to 14 years. Eur. Respir. J. 1998; 12 (suppl. 29): 25.

8. Геппе Н.А., Фарбер И.М., Малявина У.С. и др. Результаты лечения детей с бронхиальной астмой и аллергическим ринитом антагонистами лейкотриеновых рецепторов в сочетании с интервальными гипоксическими тренировками. Вопр. практ. педиатр. 2009; 3, 28-33.

9. Bisgaard H., Zielen S., GarciaGarcia M.L. et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am. J. Respir. Crit. Care Med. 2005; 171 (4): 315-322.

10. Knorr B., Franchi L.M., Bisgaard H. et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108 (3): E48.

11. Bisgaard H., Franchi L.M., Maspero J.F. et al. Long-term safety of montelukast in 2- to 5-year old children with asthma. The World Congress on Lung Health and 10th European Respiratory Society Annual Congress, Aug. 30 - Sept. 3 2000, Florence, Italy. Eur. Respir. J. 2000; 17 (3): Abs. 2152.

12. The Childhood Asthma Management Program Research Group. Longterm effect of budesonide or nedocromil in children with asthma. N. Engl. J. Med. 2000; 343: 1054-1063.

13. Bisgaard H., Gillies J., Groenewald M. et al. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children. Am. J. Respir. Crit. Care Med. 1999; 160: 126-131.

14. Bisgaard H., Munck S.L., Nielsen J.P. et al. Inhaled budesonide for treatment of recurrent wheezing in early childhood. Lanset. 1990; 336: 649-651.

15. Kemp J.P., Skoner D.P., Szefler S.J. et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann. Allergy Asthma Immunol. 1999; 83: 231-239.

16. Volovitz B., Duenas-Meza E., Chmielewska-Szewczyk D. et al. Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence: a multicenter, randomized, openlabel, crossover study in children with mild to moderate persistent asthma. Curr. Ther. Res. 2000; 61: 490-506.

17. Wowciechowska I., Duenas-Meza E., Kosa L. et al. Compliance and preference of montelukast with cromolyn in children with asthma. Allergy 1999; 54 (suppl): 25.

18. Migoya E., Kearns G.L., Hartford A. et al. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J. Clin. Pharmacol. May 2004; 44 (5): 487-494.

19. Van Adelsberg J., Moy J., Wei L.X. et al. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr. Med. Res. Opin. 2005; 21 (6): 971-979.

20. Bisgaard H. for the Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am. J. Respir. Crit. Care Med. 2003; 167: 379-383.

21. Bisgaard H., Garcia-Garcia M.L., Johnston S.L. et al. Montelukast reduces viralinduced asthma exacerbations: The PREVIA Study. Eur. Respir. J. 2004; 24: 212s.

22. Bisgaard H., Flores-Nunez A., Goh A. et al. Study of montelukast for the treatment of respiratory symptoms of postrespiratory syncytial virus bronchiolitis in children. Am. J. Respir. Crit. Care Med. 2008; 178 (8): 854-860.

23. Bisgaard H., Swern A., Tozzi C.A. et al. Efficacy of montelukast in patients aged 2 to 5 years with mild asthma. Eur. Respir. J. 2004; 24 (suppl. 48): #P2350.

24. Johnston N.W., Mandhane P.J., Dai J. et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2007; 120 (3): e702-е712.

25. Johnston S.L., Pattermore P.K., Sanderson G. et al. Community study of the role of viral infections in exacerbations of asthma in 9-11 year old children. Br. Med. J. 1995; 310: 1225-1229.

26. LaForce C.F., Pearlman D.S., Ruff M.E. et al. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. Ann. Allergy Asthma Immunol. 2000; 85: 407-415.

27. Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New development. Am. J. Respir. Crit. Care Med. 1998; 157: 1S-53S.

28. Bisgaard H., Malice M., Marshal J. et al. Randomized, placebo-controlled study of montelukast for treatment of post-RSV-bronchiolitic respiratory symptoms in children. Allergy 2007; 62 (suppl. 83): 127-127.

29. Robertson C.F., Henry R.L., Mellis C. et al. Short course montelukast for intermittent asthma in children: the Pre-Empt Study. In: 100th International conference American Thoracic Society, May 21-26, 2004, Orlando, Florida, USA: Abstract. Orlando; 2004. A53.

30. GINA. Global strategy for the diagnosis and management of asthma on children 5 years and younger. 2009: www.gin-asthma.org